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Abstract 
Objective: To investigate the incidence of high-risk human papillomavirus (HPV) infection 
and its clinical meaning.  
Methods: Total 28,339 women attending our hospital for routine gynecologic care under-
went Papanicolaou test (PAP test) and high-risk HPV tests. Biopsies were taken from some 
women and their results were compared.  
Results: The prevalence of high-risk HPV infection is 24.15%. And the women aged 20-29 
years had the highest prevalence (32.3%) compared to 30-70 years (P<0.05). Of the 28,339 
women, 1369 (4.83%) had positive PAP test (ASCUS, LSIL, HSIL). Of the 1369 PAP-positive 
patients, only 16 (1.17%) were negative for HPV test. Of the 1353 patients positive on both 
tests, 510 (37.7%) had lesions higher than CINII on histology. Of the 1,611 patients who 
underwent biopsies, 350 underwent the loop electrical excision procedure, with 339 (96%) 
being positive for HPV test, including 16 with CINI, 48 with CINII/III, 74 with CIS, and 16 with 
cervical cancer. HPV test had a positive predictive value of 40.7% and a negative predictive 
value of 100% for higher than CINII.  
Conclusion: Although HPV test has a burden of cost, considering its high negative predictive 
value, HPV test should be considered for more useful screening test. 
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Introduction 
In contrast to other types of cancer, uterine cer-
vical cancer can be diagnosed at a preinvasive stage. 
Treatment  outcomes at this stage are excellent, and 
appropriate  screening  can  lead  to  early  treatment, 
before progression to cervical cancer, and a complete 
cure. Thus, the establishment of an effective and rea-
sonable screening method would be more economical 
and effective than the development of good therapies 
for cervical cancer. 
To  date,  several  methods  have  been  used  to 
screen  for  early  stages  of  cervical  cancer,  including 
PAP test and, more recently, HPV tests. We evaluated 
the  incidence  of  high-risk  HPV  infection  in  Korean 
women and assessed  whether a combination of the 
two  can  enhance  screening  for  cervical  cancer  and 
whether the HPV test can be used to screen for pre-
invasive stages of cervical cancer. 
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Material and Methods 
We assessed 28,339 women who visited the De-
partment of Gynecologic Oncology at Saint Vincent 
Hospital  of  the  Catholic  University  of  Korea  from 
1999 to 2009 for routine gynecologic examinations and 
underwent PAP and HPV tests. HPV tests were con-
ducted using an  in vitro hybridization assay (HC  II 
HPV DNA test, Digene). Patients who previously di-
agnosed  any  other  malignancy  including  cervical 
cancer were excluded. 
Biopsy  samples  were  taken  from  patients  sus-
pected of having preinvasive or cervical cancer; these 
samples  were  assessed  histologically,  and  those  di-
agnosed as having higher than CINII stage were as-
sessed for association with positivity on the HPV test 
using ANOVA. 
Results 
Of the 28,349 women assayed, 1369 (4.83%) had 
positive results of PAP tests (ASCUS, LSIL, HSIL) and 
6,843 (24.1%) were positive for HPV. Of the 1369 PAP 
positive patients, 1,353 (98.8%) were positive and 16 
(1.17%) were negative for HPV (Table 1).  
 
Table 1. Results of PAP and HPV tests. 
  HPV Negative    HPV Positive  Total 
PAP Negative  2,1490  5,490  26,980 
PAP positive  16  1,353  1,369 
Total  21,506  6,843  28,349 
 
When we assessed the HPV infected patients by 
age, we found that women aged 20-29 years had the 
highest rate (32.3%) of HPV positivity (Figure 1, Table 
2) and compared to 30-70 years it shows significant 
difference (P<0.05).  
Table 2. Rates of HPV positivity by age. 
Age (years)  HPV Negative (%)  HPV Positive (%)  Positive rate 
 0-19  41 (0.2)  19 (0.3)  31.7% 
20-29  1184 (5.5)  565 (8.2)  32.3% 
30-39  4903(22.8)  1677(24.5)  25.5% 
40-49  8235(38.3)  2517(36.8)  23.4% 
50-59  4789(22.3)  1319(19.3)  21.6% 
60-69  1819 (8.5)   586 (8.6)  24.4% 
70-   535 (2.5)   160 (2.3)  23.0% 
Total  21506(100)  6843(100)  24.1% 
 
 Biopsy samples were taken from 1,611 patients. 
The  flow  sheet  for  their  management  is  shown  in 
Figure 1 and their age distribution is shown in Table 3 
and Figure 2. Of the 6.843 HPV positive women, 510 
(7.45%) were histologically higher than CINII. In con-
trast,  only  1  of  511  (0.2%)  HPV  negative  women 
showed histologic results higher than CINII. Of the 
1353 women positive on both PAP and HPV tests, 510 
(37.97%) had lesions histologically higher than CINII. 
To determine whether HPV titer was associated 
with  cervical  diseases,  we  divided  patients  into  4 
groups based  on HPV titer (Table 4). However, we 
found no correlation between HPV titer and disease 
status (P>0.05). 
 
 
Figure 1. Flow sheet of patient management. The numbers in parentheses are the numbers of patients. Int. J. Med. Sci. 2012, 9 
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Figure 2. Prevalence of HPV positive patients with higher than CIN II histology according to age. 
 
 
Table 3. Pathologic findings of patients with abnormal PAP test results.  
 
Age 
(years) 
 
Negative 
 
Inflammation 
 
Others 
 
CINI 
 
CIN II 
 
CINIII/CIS 
 
Invasive 
cancer 
 
Total 
*Pathologic 
positive rate (%) 
0-19  1  0  1  0  0  0  0  2  0 
 
20-29  7  440  16  11  27  18  3  522  48 
(9.2) 
30-39  8  152  16  36  62  81  17  372  160 
(43.0) 
40-49  7  182  28  46  72  91  28  454  191 
(42.1) 
50-59  9  49  12  13  16  30  18  147  64 
(43.5) 
60-69  4  33  3  7  11  13  6  77  30 
(39.0) 
70<  0  15  2  2  5  7  6  37  18 
(48.6) 
* Pathologically positive: patients with CINII, CIN III, CIS, or Invasive cancer 
 
 
Table 4. HPV titer (data/control ratio) and disease distribution in HPV positive patients (%). 
Disease  HPV titer (data/control ratio) 
1-100  100-500  500-1000  1000-2000  2000< 
Negative  70.0  20.0  10.0  0  0 
Inflammation  27.9  11.2   1.6  57.5  1.6 
CINI  94.7   2.1   0.8   1.5  0.9 
CINII/III  44.0  27.3  13.0  10.7  4.8 
CIS  45.9  15.3  14.4  26.1  2.7 
Invasive cancer  44.0  18.5   3.7  29.6  3.7 
Others  46.1  34.6  11.5  0  7.6 
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Discussion 
PAP test is used to identify preinvasive cervical 
lesions, thus allowing appropriate treatment, not to 
diagnose  invasive  cervical  cancer.  Most  clinicians 
recommend yearly screening tests for cervical cancer 
starting at around age 21 years or within 3 years of the 
initiation  of  sexual  activity.  Twice  yearly  testing  is 
recommended for patients with suppressed immuni-
ty, such as those with HIV/AIDS, after recommencing 
sexual activity (1).  
Until around age 30 years, conventional PAP test 
should be performed annually, with liquid-based tests 
performed  every  other  year.  After  age  30  years, 
women  who  are  not  immunosuppressed  and  those 
with 3 consecutive annual negative results should be 
tested every 2-3 years. Although women aged 65 to 70 
years with three consecutive negative results may not 
have to be screened for cervical cancer for the next 10 
years, regional differences should be considered (2, 3). 
While  total  hysterectomy  makes  screening  tests  for 
cervical  cancer  meaningless,  women  who  have  un-
dergone subtotal hysterectomy or total hysterectomy 
for  noninvasive  or  invasive  cervical  cancer  require 
screening similar to the general population (4). 
Although PAP test is the easiest and most widely 
available tests for cervical cancer, correct test results 
are difficult to obtain in women with lesions located 
in the endocervix or endometrium, as well as in pa-
tients with glandular neoplasms. PAP test is also not 
considered  appropriate  for  immunosuppressed  pa-
tients, patients exposed to diethylstilbestrol in utero, 
and patients being followed up after diagnosis of and 
treatment for cervical cancer (5).  
Liquid-based PAP tests are as sensitive as con-
ventional  PAP  test,  while  also  being  able  to  assay 
specimens inadequate for the latter (6). Liquid-based 
PAP tests have other advantages, including the ability 
to repeatedly test identical specimens. In addition, the 
specificity of liquid-based tests is as high as that of 
conventional Pap tests in screening for endocervical 
neoplasia and atypical glandular cells (AGC) (7). To 
date, however, the results of liquid based tests have 
not been accepted by all clinicians and the cost of such 
tests is higher than that of the conventional PAP test. 
Since HPV infection of the reproductive system 
has been shown to be a direct cause of cervical cancer, 
assays of HPV infection have been used to diagnose 
this  neoplasm.  Molecular  biological  tests  for  HPV 
DNA  can  be  broadly  classified  as  hybrid  capture 
(HCII) methods, which simultaneously screen for 13 
viral types, and PCR methods, using consensus pri-
mers. The sensitivity and specificity of both methods 
are higher than those of PAP tests (8).  
We found that the prevalence of high risk HPV 
infection was 24.5%. Of these patients, 19.8% showed 
more than ASCUS lesions on PAP test. It is considered 
cost effective to perform HPV tests when PAP test is 
abnormal.  Women  with  abnormal  findings  on  PAP 
tests are usually re-examined and tested by HPV tests. 
Women  who  undergo  both  PAP  and  HPV  tests  at 
their initial visit they have to pay the costs of HPV test 
even their PAP results are negative. In contrast, their 
results of PAP tests are higher than ASCUS can save 
the cost and time for a second visit. In sometimes due 
to the false negativity of PAP test and the psycholog-
ical burden of PAP test results, the decision to per-
form HPV tests depend on each patient. Furthermore 
in  geographic  areas  of  high  cervical  cancer  preva-
lence, it may be more cost effective and convenient to 
perform  conventional  PAP  and  HPV  tests  simulta-
neously although the frequency of liquid-based PAP 
tests are increasing, thus reducing the inconvenience 
of collecting specimens twice.  
In our results women aged 20-29 years had the 
highest frequency of HPV infection. But considering 
the first sexual experiences and a social atmosphere 
that discourages visits to obstetrics/gynecology clin-
ics, women aged 0-19 years may have the higher fre-
quency than they are showed.  
When we assessed the age distribution of HPV 
infected patients with disease higher than CINII, we 
found the highest frequency in women older than 70 
years;  however,  the  number  of  individuals  in  this 
group was quite small. We also observed a relatively 
even distribution in women aged 30 to 59 years. 
The  titer  is  generally  thought  to  be  related  to 
severity of cervical lesion but it is not real. Although 
in general women with more severe cervical lesions 
had higher titers of HPV, a low titer cannot exclude 
the possibility of more severe lesions, suggesting that 
many factors, not only HPV, are related to the patho-
genesis of cervical cancer.    
Over 90% of women with HSIL or cervical cancer 
had high risk HPV. Thus it is clear that HPV test is a 
very useful tool for cervical cancer screening. There-
fore, although HPV test has a burden of cost, consid-
ering  its  high  negative  predictive  value,  HPV  test 
should be considered for more useful screening test. 
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